Donor choice according to age for allo-SCT for AML in complete remission

Francis Ayuk Ayuketang; T Zabelina; F Wortmann; H Alchalby; C Wolschke; H Lellek; U Bacher; A Zander; N Kröger

doi:10.1038/bmt.2013.14

Donor choice according to age for allo-SCT for AML in complete remission

Standard

Donor choice according to age for allo-SCT for AML in complete remission. / Ayuketang, Francis Ayuk; Zabelina, T; Wortmann, F; Alchalby, H; Wolschke, C; Lellek, H; Bacher, U; Zander, A; Kröger, N.

In: BONE MARROW TRANSPL, Vol. 48, No. 8, 01.08.2013, p. 1028-32.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Ayuketang, FA, Zabelina, T, Wortmann, F, Alchalby, H, Wolschke, C, Lellek, H, Bacher, U, Zander, A & Kröger, N 2013, 'Donor choice according to age for allo-SCT for AML in complete remission', BONE MARROW TRANSPL, vol. 48, no. 8, pp. 1028-32. https://doi.org/10.1038/bmt.2013.14

APA

Ayuketang, F. A., Zabelina, T., Wortmann, F., Alchalby, H., Wolschke, C., Lellek, H., Bacher, U., Zander, A., & Kröger, N. (2013). Donor choice according to age for allo-SCT for AML in complete remission. BONE MARROW TRANSPL, 48(8), 1028-32. https://doi.org/10.1038/bmt.2013.14

Vancouver

Ayuketang FA, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H et al. Donor choice according to age for allo-SCT for AML in complete remission. BONE MARROW TRANSPL. 2013 Aug 1;48(8):1028-32. https://doi.org/10.1038/bmt.2013.14

Bibtex

@article{f9d565260fd74976b4dcdf5ac5cc58f8,

title = "Donor choice according to age for allo-SCT for AML in complete remission",

abstract = "In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.",

keywords = "Adult, Age Factors, Donor Selection, Female, Hematopoietic Stem Cell Transplantation, Humans, Leukemia, Myeloid, Acute, Living Donors, Male, Remission Induction, Retrospective Studies, Survival Analysis, Treatment Outcome",

author = "Ayuketang, {Francis Ayuk} and T Zabelina and F Wortmann and H Alchalby and C Wolschke and H Lellek and U Bacher and A Zander and N Kr{\"o}ger",

year = "2013",

month = aug,

day = "1",

doi = "10.1038/bmt.2013.14",

language = "English",

volume = "48",

pages = "1028--32",

journal = "BONE MARROW TRANSPL",

issn = "0268-3369",

publisher = "NATURE PUBLISHING GROUP",

number = "8",

}

RIS

TY - JOUR

T1 - Donor choice according to age for allo-SCT for AML in complete remission

AU - Ayuketang, Francis Ayuk

AU - Zabelina, T

AU - Wortmann, F

AU - Alchalby, H

AU - Wolschke, C

AU - Lellek, H

AU - Bacher, U

AU - Zander, A

AU - Kröger, N

PY - 2013/8/1

Y1 - 2013/8/1

N2 - In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

AB - In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD ≤39 years vs MRD >39 years (66% vs 34%, P=0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD ≤39 years, both MRD >39 years (relative risk (RR): 4.31, P=0.001) and UD >39 years (RR: 2.14, P=0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P=0.02). Subgroup analyses of patients ≥50 years (n=76) revealed similar results, with 5-yr OS of 62% for UD ≤39 yrs and 26% for MRD >39 yrs (P=0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.

KW - Adult

KW - Age Factors

KW - Donor Selection

KW - Female

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Leukemia, Myeloid, Acute

KW - Living Donors

KW - Male

KW - Remission Induction

KW - Retrospective Studies

KW - Survival Analysis

KW - Treatment Outcome

U2 - 10.1038/bmt.2013.14

DO - 10.1038/bmt.2013.14

M3 - SCORING: Journal article

C2 - 23419435

VL - 48

SP - 1028

EP - 1032

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 8

ER -